Connect with us

Technology

Imbed Biosciences’ DualGuard™ Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.gov

Published

on

Study Registration (NCT07695688) Supports Imbed’s Ongoing Effort to Address Biofilm — a Persistent Challenge Across Wound Care and Beyond

MIDDLETON, Wis., Oct. 1, 2026 /PRNewswire/ — Imbed Biosciences, developer of the SAMatrix™ (Synthetic Antimicrobial Matrix) technology platform, today announced that its FDA-approved IDE study evaluating the safety of investigational DualGuard™ Silver-Gallium Matrix in split-thickness skin graft donor site wounds is now registered on ClinicalTrials.gov (NCT07695688). The study will be conducted at three American Burn Association (ABA)-verified burn centers. This milestone advances DualGuard’s clinical development and reflects Imbed’s broader pursuit of solutions to address the evolving challenges biofilm presents across healthcare.

Imbed Biosciences registers first clinical study of gallium in a wound care matrix on ClinicalTrials.gov

About SAMatrix™ Technology

SAMatrix™ (Synthetic Antimicrobial Matrix) technology — or SAM, for short — was developed to address the complex, multifactorial needs of serious wounds. As a synthetic, resorbable matrix impregnated with antimicrobial silver, SAM integrates multiple wound care agents into a single product. Two versions are currently on the market: the core silver formulation, and PainGuard®, which adds lidocaine HCl to help manage pain. SAM products can be used at the onset of wound treatment, following debridement, or in surgery, including alongside other wound management technologies.

The Innovation: Adding Gallium — A “Double Punch” Against Drug-Resistant Bacteria

Building on the established silver SAMatrix™ platform, Imbed developed DualGuard™, a Silver-Gallium formulation that adds gallium as a second, synergistic antimicrobial agent within the same matrix architecture.

Gallium’s antimicrobial activity works by mimicking ferric iron, disrupting the iron-dependent metabolism many bacteria rely on in iron-limited environments. Because Ga³⁺ closely resembles Fe³⁺, bacteria take it up through their iron-acquisition pathways — but Ga³⁺ cannot support the Fe³⁺/Fe²⁺ redox cycling those pathways depend on, disrupting bacterial metabolism, growth, and biofilm-related activity.

This mechanism is distinct from both conventional antibiotics and silver. Research shows silver and gallium can act synergistically against bacteria, including within biofilm — the basis for what Imbed calls a “Double Punch”: two independent, non-overlapping antimicrobial mechanisms delivered from a single, resorbable matrix.

“By combining silver and gallium’s distinct, synergistic mechanisms, we believe DualGuard™ has the potential to address an important unmet need in complex wound care, and this study is designed to generate the clinical safety data needed to guide its continued development. Our SAM platform was built to deliver multiple wound care benefits from a single, synthetic matrix — and DualGuard™ represents the next frontier of that mission. This study’s registration on ClinicalTrials.gov is a landmark moment for Imbed Biosciences and for the field of antimicrobial wound care. We are proud to be first to bring gallium in a wound care matrix to human clinical evaluation, and grateful to our clinical partners for their continued collaboration on this program.”  — Terry Bromley, CEO

Preclinical Evidence: Activity Against Multispecies Biofilms

In preclinical studies using multispecies biofilms of Pseudomonas aeruginosa and Staphylococcus aureus grown on gauze, a single 24-hour application of the Silver-Gallium SAM technology achieved:

7.1 log₁₀ reduction in Pseudomonas aeruginosa4.2 log₁₀ reduction in Staphylococcus aureus

These data provide the scientific rationale for evaluating DualGuard™’s safety and performance in human clinical studies.

From FDA Approval to First Patient

In March 2025, FDA granted Investigational Device Exemption (IDE) approval for a clinical study evaluating DualGuard™ in human donor site wounds. With subsequent regulatory and institutional requirements — including IRB and human research oversight approvals — now satisfied, the study is ready to enroll patients in a multi-center, open-label, randomized, split-wound controlled trial of 53 subjects. Each enrolled subject’s donor site wound is divided into proximal and distal halves, with each half randomized to either DualGuard™ or a control dressing, providing an internally controlled comparison within a single patient.

Primary Objective: To evaluate the safety of DualGuard™, including adverse event occurrence and infection rates.

Secondary Objective: To evaluate effectiveness, including incidence of complete wound closure (re-epithelialization without drainage or dressing requirements), confirmed at two consecutive visits (Day 14 and Day 28).

Study Registered at ABA-Verified Burn Centers

With all regulatory and institutional requirements satisfied, the study is now registered on ClinicalTrials.gov and will be conducted at three ABA-verified burn centers — the field’s gold standard for burn center quality — ensuring enrolled patients will receive care from multidisciplinary teams experienced in burn and reconstructive wound management. To the Company’s knowledge, this will mark the first clinical evaluation of gallium incorporated within a wound care matrix. The primary objective of this initial phase is to characterize the safety and tolerability of DualGuard™. Data generated from the study are expected to inform Imbed’s future regulatory strategy for DualGuard™.

Looking Ahead

Imbed will provide updates as the study progresses, continuing its mission to develop next-generation antimicrobial technologies that address the growing threat of drug-resistant infection in wound care.

Development Funding Support

Funding for Imbed’s Silver-Gallium matrix comes in part from Small Business Innovation Research (SBIR) grants #SB1AR079347 and #R44AR073710 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, part of NIH), and a research contract awarded through the Medical Technology Enterprise Consortium (MTEC) by the U.S. Army Medical Research and Development Command’s (USAMRDC) Military Infectious Diseases Research Program (MIDRP), for prototype solutions preventing combat wound infections following blast injuries and burns.*

About Imbed Biosciences

Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its SAMatrix™ technology. The platform incorporates multiple therapeutic agents into an ultra-thin, biocompatible matrix that helps support skin regeneration in chronic and acute wounds. Imbed’s expanding portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the wound care continuum.

*Effort sponsored by the Government under Other Transaction Number W81XWH-15-9-0001.  The views expressed in this press release are those of the author and do not necessarily reflect the official policy or position of the U.S. Army, Department of War, nor the U.S. Government.

Media & Investor Contact
Hillary Rush
Vice President, Marketing
Imbed Biosciences
hrush@imbedbio.com
www.imbedbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/imbed-biosciences-dualguard-silver-gallium-matrix-safety-study-now-registered-on-clinicaltrialsgov-302896095.html

SOURCE Imbed Biosciences

Continue Reading

Technology

LoanBud Launches LoanBud Acquire™ to Expand Financing for Main Street Business Acquisitions

Published

on

By

New non-SBA program offers $100,000 to $350,000 in financing for qualified buyers acquiring established small businesses.

NEW YORK, Oct. 1, 2026 /PRNewswire/ — LoanBud today announced the launch of LoanBud Acquire™, a new non-SBA business acquisition financing program offering $100,000 to $350,000 in financing for qualified buyers acquiring established, cash-flowing small businesses.

LoanBud created the program around a problem it sees in the market every day: smaller business acquisitions can be disproportionately difficult to finance. Many lenders prioritize larger credits, while smaller transactions may not fit every SBA or conventional lending program. That can leave qualified buyers and viable businesses with fewer financing paths, even when the underlying transaction makes sense.

“A $250,000 acquisition matters just as much to the buyer, the seller and the employees as a multimillion-dollar transaction,” said Burke Purcell, Founder and CEO of LoanBud. “But smaller acquisitions can be harder to finance because many lenders tend to prioritize larger transactions. LoanBud Acquire™ gives qualified buyers another path to ownership and helps more good Main Street businesses continue under a new owner.”

LoanBud Acquire™ complements LoanBud’s existing SBA business acquisition financing capabilities. By adding a non-SBA option, LoanBud can evaluate an acquisition across multiple potential financing paths rather than trying to fit every transaction into a single program.

That flexibility can be especially important in a business sale, where financing uncertainty creates friction for the buyer, seller and broker. Earlier clarity on whether a transaction has a viable financing path can help all parties move forward with greater confidence.

LoanBud Acquire™ program highlights include:

$100,000 to $350,000 in financingMinimum 15% buyer equity contributionDesigned for acquisitions of established, cash-flowing businessesNo real estate collateral requirementFinancing available for eligible business purchase costs and approved transaction expensesTargeted closing timeline of less than 30 days for qualified transactions

“We do not believe every acquisition should be forced into one financing box,” Purcell said. “Our job is to look at the transaction, identify the most realistic financing path and help the buyer, seller and broker get to a clear answer faster. LoanBud Acquire™ gives us another way to do that for smaller Main Street transactions.”

LoanBud Acquire™ is available now. Qualified buyers and business brokers can learn more at LoanBud.com or apply at apply.loanbud.com.

About LoanBud

LoanBud helps existing business owners access growth capital and helps entrepreneurs finance business acquisitions. By combining technology, experienced lending professionals and a nationwide network of lending partners, LoanBud provides access to SBA and conventional financing for acquisitions, growth, real estate, debt refinancing and working capital. LoanBud is focused on making small business financing faster, clearer and easier to navigate.

For more information, visit LoanBud.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/loanbud-launches-loanbud-acquire-to-expand-financing-for-main-street-business-acquisitions-302896385.html

SOURCE LoanBud

Continue Reading

Technology

McKool Smith Named 2026 IP “Litigation Department of the Year” by Texas Lawyer

Published

on

By

DALLAS, Oct. 1, 2026 /PRNewswire/ — McKool Smith has been named Intellectual Property “Litigation Department of the Year” at the 2026 Texas Legal Awards, presented by Texas Lawyer. The Texas Legal Awards honor the attorneys and law firms making a lasting impact on the Texas legal landscape, from groundbreaking case wins to innovative legal strategies. Winners were celebrated at the awards ceremony on September 30 in Dallas.

The firm recognition reflects a track record of success in high-stakes IP disputes. In the Eastern District of Texas, Austin Principal Steve Pollinger, as lead counsel, along with Marshall Principal Jennifer Truelove, won a $192 million verdict for Mojo Mobility against Samsung on wireless charging patents that was held in full at final judgment. Jennifer also served as co-lead trial counsel on a willful infringement verdict for Pictiva Displays against Samsung on OLED display patents. At the U.S. International Trade Commission (ITC), the firm’s campaign for Nokia against Hisense ended in a global license resolving the dispute in every jurisdiction.

The department’s recent results also include a stretch of significant trial wins for Dallas Principal Warren Lipschitz, a finalist for Intellectual Property Attorney of the Year. In August 2026, he co-led a team in securing a complete defense verdict for AT&T, Verizon, T-Mobile, Ericsson and Nokia in a consolidated 5G patent trial in the Eastern District of Texas, defeating $436 million in claimed damages. The jury found no infringement, invalidated all nine asserted claims, and held that the plaintiffs had breached their own FRAND obligations. That verdict followed back-to-back 2025 defense wins Warren co-led against Daingean Technologies, also in the Eastern District, cutting a $245 million demand against T-Mobile to $2 million and then winning a verdict of no infringement for AT&T. On the plaintiff side, Warren secured an ITC Initial Determination for Nokia that Amazon infringed five of seven asserted patents, and Nokia reached a settlement with Amazon shortly thereafter.

With more than 130 trial lawyers across offices in Austin, Dallas, Houston, Los Angeles, Marshall, New York, and Washington, D.C., McKool Smith has established a reputation as one of America’s leading trial firms. The firm has secured 18 nine-figure jury verdicts and 16 eight-figure jury verdicts, obtaining more VerdictSearch and The National Law Journal “Top 100 Verdicts” than any other law firm. McKool Smith represents clients in complex commercial litigation, intellectual property, bankruptcy, and white-collar defense matters.

View original content:https://www.prnewswire.com/news-releases/mckool-smith-named-2026-ip-litigation-department-of-the-year-by-texas-lawyer-302896389.html

SOURCE McKool Smith

Continue Reading

Technology

Custom Home Builder Selection in Lexington SC Guidance Outlined in HelloNation Featuring Home Building Expert Jennifer L. Gerben Nettles

Published

on

By

The article explains how early consultation with a builder can help evaluate land suitability, site conditions, and construction costs before purchasing property.

LEXINGTON, S.C., Oct. 1, 2026 /PRNewswire/ — Do prospective homeowners need to own land before hiring a custom home builder in Lexington, South Carolina? HelloNation addresses that question in a HelloNation article that explores how early collaboration with a builder can help guide land selection and project planning.

The HelloNation article explains that many buyers assume they must purchase land before contacting a custom home builder Lexington SC professional. In practice, involving a builder earlier in the process can offer important advantages. Builders can help assess potential properties and identify factors that may influence construction feasibility, costs, and design options before a purchase is finalized.

One of the first considerations discussed in the article is the building potential of the land itself. Not all lots offer the same conditions for residential construction. Soil composition, grading, and topography can significantly affect how easily a home can be built. The article notes that a lot that appears ideal at first glance may require extensive excavation, retaining walls, or drainage work, all of which can increase project costs.

Evaluating site conditions before purchasing land can help homeowners avoid unexpected challenges later in the building process. According to the article, builders can conduct early assessments to determine whether the lot can accommodate the desired home design. Home Building Experts explain that this evaluation helps identify potential construction limitations and provides a clearer picture of the work required to prepare the site.

Utility access is another major factor that may influence whether a lot is suitable for a custom home Lexington SC project. The article describes how water, sewer, electricity, and internet service are not always readily available on undeveloped parcels of land. Connecting a property to these utilities may involve additional infrastructure work, which can increase both cost and project timelines. Builders who understand local infrastructure can help estimate the feasibility and expense of utility installation before a buyer commits to purchasing a property.

Lot shape and size can also affect design possibilities and construction costs. The HelloNation article explains that narrow or irregularly shaped parcels may limit the placement and layout of a home. Builders can provide guidance on how to adapt architectural plans to fit the property while still meeting the homeowner’s functional and aesthetic goals. This type of planning ensures that the home design works within the constraints of the lot.

Budget planning is another reason the article recommends early consultation with a custom home builder Lexington SC professional. Builders can provide preliminary construction estimates that account for site preparation, grading, permits, and other development requirements tied to a specific lot. This information helps prospective homeowners determine whether a property aligns with their financial plans before making a purchase.

The article also discusses how early collaboration can streamline the permitting and planning process. Builders with experience in Lexington understand local zoning regulations, setback requirements, and building codes that influence how a home can be placed on a lot. Home Building Experts explain that reviewing these regulations early can prevent costly redesigns or delays later in the project.

Working with a builder during the land selection stage also allows homeowners to compare multiple properties more effectively. By reviewing site conditions, infrastructure access, and potential construction challenges, buyers can make more informed decisions about which lot best supports their vision for a custom home.

The HelloNation article emphasizes that purchasing land first is not always required when planning a custom build. Instead, involving a builder early in the process can create a smoother path from property selection to construction. Evaluating grading requirements, infrastructure availability, and lot suitability ahead of time helps homeowners avoid surprises and better align their plans with realistic construction expectations.

Do You Need Land Before Hiring a Custom Home Builder? features insights from Jennifer L. Gerben Nettles, Home Building Expert of Lexington, South Carolina, in HelloNation.

About HelloNation
HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative “edvertising” approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/custom-home-builder-selection-in-lexington-sc-guidance-outlined-in-hellonation-featuring-home-building-expert-jennifer-l-gerben-nettles-302896381.html

SOURCE HelloNation

Continue Reading

Trending